Immune Thrombocytopenia (Itp) In Emergency Medicine

Life Sciences-Thrombocytopenia

Authors

  • Mohammed Salah Hussain Department of gastroenterology and endoscopy, Dr Samir Abbas Hospital,Jeddah ,Saudi Arabia and Department of Internal Medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt SCFHS number: 12RM0018323SCFHS
  • Makhdum Ghadah Mohammedanas M King fahad Armed Force hospital Jeddah
  • Alsharif Abdullah Mohammed M King fahad Armed Force hospital Jeddah
  • Abdulmajeed Abdullah Musnad Alshammari King Salman Specialist Hospital
  • Mohammed Raghad Abdullah M King Khalid University-Abha
  • Alanoud Abdullah H Althobaiti Medical intern, university of Tabuk
  • Albalawi Zainab Atallah S MATERNITY AND CHILDREN HOSPITAL-TABUK
  • Labani Amal Mohammed H King Fahad General Hospital, Jeddah
  • Alshebli Abdullah Saud A Medical intern, Qassim university
  • Alawad Abdullah Mohammed King Khaled hospital, Hail
  • Rayan Hamad Alsidrani Ayn bin fehaid PHC, alasyah general hospital
  • Alsubaie Thawab Muthyib T Rumah General hospital. Riyadh
  • Abdulrahman Mersal Aldhafeeri Kuwait University
  • Narjes Ali Alismail Prince Saud bin Jalawi hospital, Alhassa, Saudi Arabia

DOI:

https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP24.L29-36

Keywords:

ITP, Symptoms, Diagnosis, Treatment

Abstract

Immune Thrombocytopenia (ITP) is an autoimmune disorder characterised by a low platelet countless than 100? ×? 10^9/L, purpura, and hemorrhagic episodes induced by antiplatelet autoantibodies without anemia or leukopenia. Immune thrombocytopenia (ITP) occurs in 2 to 4/100? 000 adults. A wide range of signs and symptoms, from modest mucocutaneous petechiae to severe, life-threatening organ haemorrhage, are seen in ITP patients. they may present to the emergency department (ED) with life-threatening bleeding as a result of their thrombocytopenia. ITP has two distinct clinical syndromes, manifesting as an acute condition in children and a chronic condition in adults. IgG autoantibodies make circulating platelets more sensitive. It causes these cells to be removed more quickly by antigen-presenting cells (macrophages) of the spleen, and occasionally the liver or other components of the monocyte-macrophage system. Current evidence supports alternatives to splenectomy for second-line management of patients with persistently low platelet counts and bleeding. By increasing platelet production, bone marrow compensates for platelet breakdown. Immune Thrombocytopenia most commonly arises within a few weeks after a viral infection in healthy children and young adults. Immunosuppressive treatment is usually effective in treating ITP. Many patients with ITP require no emergent treatment. However, the emergency physician should start treatment with a platelet transfusion, corticosteroids, and intravenous immune globulin (IVIG) as soon as the patient with suspected ITP arrives at the ED with serious haemorrhage.The diagnosis is usually made by ruling out all known causes of thrombocytopenia. This review aims to summarize current evidences regarding prevalence, causes, diagnosis and management of immune thrombocytopenia. Keywords:,,,

References

Stasi R, Evangelista ML, Stipa E, et al. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. Thromb Haemost. 2008;99(1):4–13.

Lusher JM, Zuelzer WW. Idiopathic thrombocytopenic purpura in childhood. J Pediatr 1966;68:971-9.

Onisâi, Minodora, Vlădăreanu, Ana-Maria, Spînu, Andreea, Găman, Mihaela and Bumbea, Horia. "Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease" Romanian Journal of Internal Medicine, vol.57, no.4, 2019, pp.273-283. https://doi.org/10.2478/rjim-2019-0014

Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. PMID: 31794604s

Moller DE, Goldstein K. Hemarthrosis and idiopathic thrombocytopenic purpura. J Rheumatol 1987 Apr;14(2):382-3.

George JN, Woolf SH, Raskob GE, Wasser JS, Aledort LM, Ballem PJ, et al. Idiopathic Thrombocytopenic Purpura: A Practice Guideline Developed by Explicit Methods for The American Society of Hematology. Blood 1996;88:3-40.

Portielje JE, Westendorp RG, Kluin-Nelemans HC, et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood. 2001;97(9):2549–54.

Cooper N, Ghanima W. Immune Thrombocytopenia. N Engl J Med. 2019 Sep 5. 381 (10):945-955. [QxMD MEDLINE Link].

Kuhne T. Idiopathic thrombocytopenic purpura of childhood: a problem-oriented review of the management. Transfus Apher Sci 2003 Jun;28(2):243-8.

Fargangi H, Ghasemi A, Banihashem A, Badiei Z, Jarahi L, Esami G, Langaee T. Clinical Features and Treatment Outcomes of Primary Immune Thrombocytopenic Purpura in Hospitalized Children Under 2-Years Old. Iran J Ped Hematol Oncol. 2016; 6(1): 24-31.

Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386. doi: 10.1182/blood-2008-07-162503

Zufferey A, Kapur R, Semple J. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). JCM. 2017;6(2):16. doi: 10.3390/jcm6020016

Samson M, Fraser W, Lebowitz D. Treatments for Primary Immune Thrombocytopenia: A Review. Cureus. 2019 Oct 6;11(10):e5849. doi: 10.7759/cureus.5849. PMID: 31754584; PMCID: PMC6830854.

Fogarty PF, Segal JB. The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol. 2007;14(5):515–519.

Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85(3):174–180. doi: 10.1002/ajh.21616

Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr. 2005;94(2):178–184.

Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4(11):2377–2383.

Zeller B, Rajantie J, Hedlund-Treutiger I, et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease: childhood ITP in the Nordic countries. Acta Paediatrica. 2007;94(2):178–184. doi: 10.1111/j.1651-2227.2005.tb01887.x [

Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol. 2010;149(6):855–864.

Terrell DR, Beebe LA, Neas BR, Vesely SK, Segal JB, George JN. Prevalence of primary immune thrombocytopenia in Oklahoma. Am J Hematol. 2012;87(9):848–852. doi: 10.1002/ajh.23262

` Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR On behalf of the Northern Region Haematology Group. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Brit J Haematol. 2003;122:966–974.

Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood. 1999;94(3):909–913.

Kistangari G, McCrae KR. Immune thrombocytopenia. Hematol Oncol Clin North Am. 2013 Jun;27(3):495-520. doi: 10.1016/j.hoc.2013.03.001. PMID: 23714309; PMCID: PMC3672858.

Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;2018(1):405–411. doi: 10.1182/asheducation-2018.1.405

Stasi R. Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost. 2012;38(5):454–462.

Warrier R, Chauhan A. Management of immune thrombocytopenic purpura: an update. Ochsner J. 2012 Fall;12(3):221-7. PMID: 23049459; PMCID: PMC3448244.

The ITP syndrome: pathogenic and clinical diversity. Cines DB, Bussel JB, Liebman HA, Luning Prak ET. Blood. 2009;113:6511–6521.

Olsson B., Andersson P.O., Jernas M., Jacobsson S., Carlsson B., Carlsson L.M., Wadenvik H. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat. Med. 2003;9:1123–1124. doi: 10.1038/nm921.

Khodadi E., Asnafi A.A., Shahrabi S., Shahjahani M., Saki N. Bone marrow niche in immune thrombocytopenia: A focus on megakaryopoiesis. Ann. Hematol. 2016;95:1765–1776. doi: 10.1007/s00277-016-2703-1.

Zhang W., Nardi M.A., Borkowsky W., Li Z., Karpatkin S. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C-related immunologic thrombocytopenia. Blood. 2009;113:4086–4093. doi: 10.1182/blood-2008-09-181073.

Rodeghiero, Francesco, et al. "Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group." Blood, The Journal of the American Society of Hematology 113.11 (2009): 2386-2393.

Vayne C, Guery E, Rollin J, Baglo T, Petermann R, Gruel Y. Pathophysiology and diagnosis of drug-induced immune thrombocytopenia. J Clin Med. 2020;9(7):2212. doi: 10.3390/jcm9072212

Despotovic JM, Grimes AB. Pediatric ITP: is it different from adult ITP? Hematology Am Soc Hematol Educ Program. 2018;2018(1):405–411. doi: 10.1182/asheducation-2018.1.405

KISTANGURI G, MCCRAE K. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013; 27(3):495–520.

Newton JL, Reese JA, Watson SI, et al. Fatigue in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2011;86(5):420–429.

Nørgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639. doi: 10.1111/bjh.13787

Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann N Y Acad Sci. 1965;124(2):499-542.

Khodadi E, Asnafi AA, Shahrabi S, Shahjahani M, Saki N. Bone marrow niche in immune thrombocytopenia: a focus on megakaryopoiesis. Ann Hematol. 2016;95(11):1765-1776.

Olsson B, Andersson PO, Jernås M, et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123-1124.

Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511-6521.

Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585-596.

Malara A, Abbonante V, Di Buduo CA, Tozzi L, Currao M, Balduini A. The secret life of a megakaryocyte: emerging roles in bone marrow homeostasis control. Cell Mol Life Sci. 2015;72(8):1517-1536.

Makar RS, Zhukov OS, Sahud MA, Kuter DJ. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists. Am J Hematol. 2013;88(12):1041-1044.

Provan D, Stasi R, Newland Ac, Blanchette Vs, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010; 115:168–186.

Zitek T, Weber L, Pinzon D, Warren N. Assessment and Management of Immune Thrombocytopenia (ITP) in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2022 Jan 29;14:25-34. doi: 10.2147/OAEM.S331675. PMID: 35125895; PMCID: PMC8809484.

Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.

Purohit A, Aggarwal M, Singh PK, et al. Re-evaluation of need for bone marrow examination in patients with isolated thrombocytopenia contributors [published correction appears in Indian J Hematol Blood Transfus. 2016;32(2):197]. Indian J Hematol Blood Transfus. 2016;32(2):193-196.

DM Arnold, JG Kelton Current options for the treatment of idiopathic thrombocytopenic purpura. Semin Hematol, 44 (2007), pp. S12-S23

British Committee for Standard in Haematology General Haematology Task Force Guidelines for the investigation and management of idiopathic thrombocytopenic purpura (ITP) in adults, children and in pregnancy. Br J Haematol, 120 (2003), pp. 574-596 2003

Samson M, Fraser W, Lebowitz D. Treatments for Primary Immune Thrombocytopenia: A Review. Cureus. 2019 Oct 6;11(10):e5849. doi: 10.7759/cureus.5849. PMID: 31754584; PMCID: PMC6830854.

The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr. Jr., Crowther MA. Blood. 2011;117:4190–4207.

Cuker A., Prak E.T., Cines D.B. Can immune thrombocytopenia be cured with medical therapy? Semin. Thromb. Hemost. 2015;41:395–404.

Rudnicka D., Oszmiana A., Finch D.K., Strickland I., Schofield D.J., Lowe D.C., Sleeman M.A. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell-mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121:4694–4702. doi: 10.1182/blood-2013-02-482570.

Audia S., Samson M., Guy J., Janikashvili N., Fraszczak J., Trad M., Ciudad M., Leguy V., Berthier S., Petrella T., et al. Immunologic effects of rituximab on the human spleen in immune thrombocytopenia. Blood. 2011;118:4394–4400. doi: 10.1182/blood-2011-03-344051.

Erickson-Miller C.L., DeLorme E., Tian S.S., Hopson C.B., Stark K., Giampa L., Valoret E.I., Duffy K.J., Luengo J.L., Rosen J., et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp. Hematol. 2005;33:85–93. doi: 10.1016/j.exphem.2004.09.006.

Cohn C.S., Bussel J.B. Romiplostim: A second-generation thrombopoietin agonist. Drugs Today. 2009;45:175–188. doi: 10.1358/dot.2009.45.3.1343793.

Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829. doi: 10.1182/bloodadvances.2019000966

Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780. doi: 10.1182/bloodadvances.2019000812

Arnold DM, Cuker A. Immune thrombocytopenia (ITP) in adults: clinical manifestations and diagnosis. UpToDate. Available from: https://www.uptodate.com/contents/immune-thrombocytopenia-itp-in-adults-clinical-manifestations-and-diagnosis?search=immune%20thrombocytopenia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H21. Accessed October 22, 2021.

Tintinalli JE. Tintinalli’s Emergency Medicine. 8th ed. McGraw-Hill Companies; 2015:1491

Spahr JE, Rodgers GM. Treatment of immune-mediated thrombocytopenia purpura with concurrent intravenous immunoglobulin and platelet transfusion: a retrospective review of 40 patients. Am J Hematol. 2008;83(2):122–125.

BRYNES RK, ORAZI A, VERMA S, BRAINSKY K, BAILEY CK, BAKSHI K. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenic purpura (ITP) treated with Eltrombopag-data from the EXTEND study. Blood. 2011; 118.

KISTANGURI G, MCCRAE K. Immune Thrombocytopenia. Hematol Oncol Clin North Am. 2013; 27(3):495–520.

Davoren A, Bussel J, Curtis BR, Moghaddam M, Aster RH, McFarland JG. Prospective evaluation of a new platelet glycoprotein (GP)-specific assay (PakAuto) in the diagnosis of autoimmune thrombocytopenia (AITP). Am J Hematol. 2005;78(3):193–197. doi: 10.1002/ajh.20309

Kuhne T, Berchtold W, Michaels LA, et al. Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group. Haematologica. 2011;96(12):1831–1837. doi: 10.3324/haematol.2011.050799

Onisâi M, Vlădăreanu A-M, Spînu A, Găman M, Bumbea H. Idiopathic thrombocytopenic purpura (ITP) – new era for an old disease. Rom J Intern Med. 2019;57(4):273–283

Sarpatwari A, Bennett D, Logie JW, et al. Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom general practice research database. Haematologica. 2010;95(7):1167–1175. doi: 10.3324/haematol.2009.018390

Nørgaard M, Severinsen MT, Lund Maegbaek M, Jensen AØ, Cha S, Sørensen HT. Risk of arterial thrombosis in patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2012;159(1):109. doi: 10.1111/j.1365-2141.2012.09231.x

Nørgaard M, Cetin K, Maegbaek ML, et al. Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study. Br J Haematol. 2016;174(4):639. doi: 10.1111/bjh.13787

Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. Br J Haematol. 2014;166(2):260–267. doi: 10.1111/bjh.12869

Care A, Pavord S, Knight M, Alfirevic Z. Severe primary autoimmune thrombocytopenia in pregnancy: a national cohort study. BJOG. 2018;125(5):604–612. doi: 10.1111/1471-0528.14697

Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129(21):2829–2835. doi: 10.1182/blood-2017-03-754119

Bomhof G, Mutsaers PGNJ, Leebeek FWG, et al. COVID‐19‐associated immune thrombocytopenia. Br J Haematol. 2020;190(2). doi: 10.1111/bjh.16850

Murt A, Eskazan AE, Yılmaz U, Ozkan T, Ar MC. COVID‐19 presenting with immune thrombocytopenia: a case report and review of the literature. J Med Virol. 2021;93(1):43–45. doi: 10.1002/jmv.26138

Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med. 2020;2(11):2048–2058. doi: 10.1007/s42399-020-00521-8

Sahu KK, Siddiqui AD, Rezaei N, Cerny J. Challenges for management of immune thrombocytopenia during COVID‐19 pandemic. J Med Virol. 2020;92(11):2277–2282. doi: 10.1002/jmv.26251

Mahévas M, Moulis G, Andres E, et al. Clinical characteristics, management and outcome of COVID‐19‐associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4). doi: 10.1111/bjh.17024

Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020;506:145–148. doi: 10.1016/j.cca.2020.03.022

Published

2022-10-22

How to Cite

Salah Hussain, M., Ghadah Mohammedanas M, M., Abdullah Mohammed M, A., Abdullah Musnad Alshammari , A., Raghad Abdullah M , M. ., Abdullah H Althobaiti , A., Zainab Atallah S , A., Amal Mohammed H, L., Abdullah Saud A, A., Abdullah Mohammed, A., Hamad Alsidrani, R., Thawab Muthyib T , A. ., Mersal Aldhafeeri, A., & Ali Alismail, N. (2022). Immune Thrombocytopenia (Itp) In Emergency Medicine: Life Sciences-Thrombocytopenia. International Journal of Life Science and Pharma Research, 12(SP24), L29-L36. https://doi.org/10.22376/ijpbs/lpr.2022.12.6.SP24.L29-36

Issue

Section

Review Articles